BioVie Will Present Bezisterim Trial Findings in October
The San Diego conference will highlight results from recent studies on Parkinson's disease and Long COVID.
Updated on Oct. 14, 2026 in Alzheimer’s
BioVie will present findings from its Phase 2 clinical trials at the 2026 American Neurological Association Annual Meeting, held in San Diego from October 17-20, 2026. The presentations will feature data regarding the investigational drug bezisterim.
Why it matters
These presentations provide a look at early-stage trial results for bezisterim, which is being investigated for its potential to impact inflammatory pathways in chronic conditions.
Results come from two Phase 2 trials: the 57-patient SUNRISE-PD study in Parkinson's and a 200-patient ADDRESS-LC trial for Long COVID. Findings for ADDRESS-LC showed the study did not achieve statistical significance on endpoints in the overall intent-to-treat population.
The players
BioVie
A pharmaceutical company headquartered in Carson City, Nev., focused on developing therapies for inflammatory diseases.
American Neurological Association
A professional society of neurologists that hosts an annual meeting to discuss advancements in neurodegenerative and inflammatory research.
The details
Bezisterim is designed to modulate specific inflammatory pathways in the body, including ERK, NFκB, and TNFα. By targeting these pathways, the drug aims to reduce systemic inflammation associated with various disease states. Researchers will share these findings through poster presentations during the upcoming conference.
Timeline
October 17-20, 2026: ANA2026 conference in San Diego.
October 18, 2026: Long COVID trial findings presentation.
October 19, 2026: Parkinson's disease trial findings presentation.
Health Landscape
This disclosure follows the standard cycle of clinical data release at the American Neurological Association Annual Meeting. It situates the development of bezisterim alongside ongoing efforts to identify novel anti-inflammatory treatments for neurodegenerative and chronic conditions.
These findings are preliminary and strictly meant for research discussion. If you are managing Parkinson's disease or Long COVID, keep track of official updates through your neurologist and discuss new clinical developments as they are peer-reviewed.
The takeaway
Early clinical trial data for bezisterim will be shared publicly later this month. Patients should focus on standard-of-care treatments and consult with their physician before considering participation in or drawing conclusions from preliminary phase trials.
Further reading
Learn more about the latest research and ongoing developments in the field by visiting our Alzheimer’s section.
Source note: This article includes information reported by The Manila times.
